Poster
T-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
DESTINY-Breast06 post hoc analysis by physician’s choice of chemotherapy: Efficacy and safety of trastuzumab deruxtecan versus physician’s choice of chemotherapy in hormone receptor–positive, HER2-low or -ultralow metastatic breast cancer
Carlos H. Barrios
Poster
T-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
Exploratory biomarker analysis of trastuzumab deruxtecan versus physician’s choice of chemotherapy in HER2-low/ultralow, hormone receptor–positive metastatic breast cancer in DESTINY-Breast06
Rebecca Dent
Poster
HER3-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
HERTHENA-PanTumor01 (NCT06172478): Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic HR+/HER2− breast cancer
Funda Meric-Bernstam
Poster
T-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
Real-world safety of trastuzumab deruxtecan in HER2-low metastatic breast cancer: Insights from US community oncology practices
Mark Walker
Poster
Dato-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
Real-world study characterizing patient characteristics, treatments, and unmet need in IO-ineligible patients with metastatic triple-negative breast cancer
Marvin Nguyen
Poster
T-DXd
Miami Breast 2026 | March 5-8, 2026
Breast Cancer
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Real-world treatment patterns and outcomes from community oncology settings
Marvin Nguyen